Merck last week announced “positive” results from a Phase 2/3 clinical trial for a monoclonal antibody drug the pharmaceutical giant is developing to protect infants against respiratory syncytial virus (RSV) disease.
The drug, clesrovimab, met its safety and efficacy endpoints, …
The post Merck Unveils New RSV Shot for Babies, as Moderna Trials mRNA RSV Vaccine for Infants and Toddlers appeared first on Global Research.